Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the preventive effect of stroke between triflusal and clopidogrel in ischemic stroke patient based on the cytochrome P450 2C19 (CYP2C19) polymorphism.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gangnam Severance Hospital
• Collaborators: Myung In Pharmaceutical Company; Yonsei University
• Treatments: Clopidogrel; Salicylates; Ticlopidine; Triflusal

Criteria

Inclusion Criteria:

1. Patients who have non-cardiogenic ischemic stroke of TOAST classification within 30 days prior to screening

2. ≥ 20 years of age; adult, at the date of signing the informed consent

3. Written informed consent

Exclusion Criteria:

1. History for bleeding tendency or recent major bleeding within 2 weeks

2. Chronic liver disease (ALT > 100 IU/L or AST > 100 IU/L) or renal dysfunction (creatinine > 4.0 mg/dl)

3. Thrombocytopenia (platelet < 100,000mm3)

4. Any contraindication of antiplatelet agent

5. Severe congestive heart failure

6. Patients who need to take anticoagulants or two or more antiplatelet agents

7. Severe concomitant disease with the expected survival less than 2 years

8. Pregnant or nursing

9. Any drug clinical trials within 30 days of signing the informed consent